Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

BACKGROUND: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. METHODS: ODYSSEY OUTCOMES (Evaluation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Steg, Philippe Gabriel, Szarek, Michael, Bhatt, Deepak L., Bittner, Vera A., Brégeault, Marie-France, Dalby, Anthony J., Diaz, Rafael, Edelberg, Jay M., Goodman, Shaun G., Hanotin, Corinne, Harrington, Robert A., Jukema, J. Wouter, Lecorps, Guillaume, Mahaffey, Kenneth W., Moryusef, Angèle, Ostadal, Petr, Parkhomenko, Alexander, Pordy, Robert, Roe, Matthew T., Tricoci, Pierluigi, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Schwartz, Gregory G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661243/
https://www.ncbi.nlm.nih.gov/pubmed/31117810
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661243/
https://www.ncbi.nlm.nih.gov/pubmed/31117810
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038840

Ejemplares similares